Ficha del valor · trimestre archivado
RVMD
Revolution Medicines, Inc. · Healthcare · Biotechnology
11Tenedores rastreados
—Δ titulares
28.23MAcciones mantenidas
$999.53MValor declarado
+0Nuevas posiciones
−0Cierres
Todas las cifras de propiedad: únicamente gestores 13F seguidos, posiciones en acciones ordinarias, período de referencia Q2 2024
Participación a lo largo del tiempo
| Trimestre | Titulares | Δ | Acciones | Valor declarado | Nuevo | Cierres |
|---|---|---|---|---|---|---|
| Q2 2026 | 149 | +17 | 106.81M | $18.63B | +25 | −7 |
| Q1 2026 | 134 | +17 | 103.45M | $9.43B | +22 | −6 |
| Q4 2025 | 116 | +1 | 107.70M | $8.12B | +3 | −1 |
| Q3 2025 | 20 | +3 | 68.96M | $3.10B | +3 | −1 |
| Q2 2025 | 15 | 0 | 63.88M | $2.26B | — | — |
| Q1 2025 | 12 | +2 | 32.32M | $1.05B | +2 | — |
| Q4 2024 | 10 | -1 | 33.19M | $1.34B | — | −1 |
| Q3 2024 | 10 | -1 | 26.28M | $1.08B | — | −1 |
| Q2 2024 | 11 | — | 28.23M | $999.53M | — | — |
Quién lo tiene en cartera · Q2 2024
| # | Gestor | Acciones | Δ acciones | Valor | Su ponderación | Mantenida | ||
|---|---|---|---|---|---|---|---|---|
| 1 | Wellington Management ✦ | 13.66M | — | $530.15M | 0.1% | n/c | 1 | SEC ↗ |
| 2 | Wellington Management ✦ | 13.66M | — | $530.15M | 0.1% | n/c | 1 | SEC ↗ |
| 3 | Wellington Management ✦ | 13.66M | — | $530.15M | 0.1% | n/c | 1 | SEC ↗ |
| 4 | Wellington Management ✦ | 13.66M | — | $530.15M | 0.1% | n/c | 1 | SEC ↗ |
| 5 | Wellington Management ✦ | 13.66M | — | $530.15M | 0.1% | n/c | 1 | SEC ↗ |
| 6 | Wellington Management ✦ | 13.66M | — | $530.15M | 0.1% | n/c | 1 | SEC ↗ |
| 7 | Wellington Management ✦ | 13.66M | — | $530.15M | 0.1% | n/c | 1 | SEC ↗ |
| 8 | Wellington Management ✦ | 13.66M | — | $530.15M | 0.1% | n/c | 1 | SEC ↗ |
| 9 | T. Rowe Price ✦ | 5.82M | — | $202.50M | 0.0% | n/c | 1 | SEC ↗ |
| 10 | T. Rowe Price ✦ | 5.82M | — | $202.50M | 0.0% | n/c | 1 | SEC ↗ |
| 11 | T. Rowe Price ✦ | 5.82M | — | $202.50M | 0.0% | n/c | 1 | SEC ↗ |
| 12 | Geode Capital Management ✦ (pasivo) | 3.34M | — | $129.48M | 0.0% | n/c | 1 | SEC ↗ |
| 13 | Geode Capital Management ✦ (pasivo) | 3.34M | — | $129.48M | 0.0% | n/c | 1 | SEC ↗ |
| 14 | Norges Bank ✦ (pasivo) | 1.85M | — | $71.75M | 0.0% | n/c | 1 | SEC ↗ |
| 15 | Marshall Wace ✦ | 816.05K | — | $31.67M | 0.0% | n/c | 1 | SEC ↗ |
| 16 | Citadel Advisors ✦ | 439.12K | — | $15.87M | 0.0% | n/c | 1 | SEC ↗ |
| 17 | Citadel Advisors ✦ | 439.12K | — | $15.87M | 0.0% | n/c | 1 | SEC ↗ |
| 18 | Citadel Advisors ✦ | 439.12K | — | $15.87M | 0.0% | n/c | 1 | SEC ↗ |
| 19 | Point72 Asset Management ✦ | 227.92K | — | $8.85M | 0.0% | n/c | 1 | SEC ↗ |
| 20 | Adage Capital Partners ✦ | 670.00K | — | $6.65M | 0.0% | n/c | 1 | SEC ↗ |
| 21 | Adage Capital Partners ✦ | 670.00K | — | $6.65M | 0.0% | n/c | 1 | SEC ↗ |
| 22 | D. E. Shaw & Co. ✦ | 1.38M | — | $1.23M | 0.0% | n/c | 1 | SEC ↗ |
| 23 | D. E. Shaw & Co. ✦ | 1.38M | — | $1.23M | 0.0% | n/c | 1 | SEC ↗ |
| 24 | D. E. Shaw & Co. ✦ | 1.38M | — | $1.23M | 0.0% | n/c | 1 | SEC ↗ |
| 25 | Two Sigma Investments ✦ | 22.76K | — | $883,199 | 0.0% | n/c | 1 | SEC ↗ |
| 26 | AQR Capital Management ✦ | 12.83K | — | $498,010 | 0.0% | n/c | 1 | SEC ↗ |
| 27 | AQR Capital Management ✦ | 12.83K | — | $498,010 | 0.0% | n/c | 1 | SEC ↗ |
«Su ponderación» = la participación de la posición en el valor de renta variable 13F declarado por ese gestor — la medida de convicción. ✦ = gestor seleccionado.
Nuevos compradores
| Sin nuevos compradores rastreados este trimestre. |
Posición cerrada
| Sin salidas rastreadas este trimestre. |
Contexto de mercado completo: entre TODOS los filers 13F (datos estructurados SEC, Q1 2026): 1 tenedores, 13.50K acciones, $1,312 declarado. Este es un período diferente y anterior al de las cifras del universo rastreado que figuran arriba, y ambos nunca se mezclan.
Frecuentemente cotituladas
Qué otros valores suelen tener también los tenedores rastreados de este activo — recuentos de cotenencia, no relaciones fundamentales.
Procedencia: Participación a partir de posiciones en acciones ordinarias de 13F procesadas (universo rastreado, conjuntos comparables para cambios); filas de iniciados de los Formularios 3/4/5; participaciones de los Schedules 13D/13G; cada filing enlaza con su original en SEC EDGAR.
Período de reporte: Q2 2024 ·
Metodología ·
Obtener esto a través de la API